Evidence map›Paper›PMID 35415708›Full record

ArticleWomen's health reports (New Rochelle, N.Y.)2022

The Burden of Uterine Fibroids from the Perspective of US Women Participating in Open-Ended Interviews.

Elke Hunsche, Viatcheslav Rakov, Kayla Scippa, Brooke Witherspoon, Laura McKain

2 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Women's health reports (New Rochelle, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03049735 phase3completednot on this map

LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

TypeinterventionalSponsorMyovant Sciences GmbHRan2017 to 2020Enrolled388ConditionsHeavy Menstrual Bleeding, Uterine FibroidArmsRelugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
NCT03103087 phase3completednot on this map

LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

TypeinterventionalSponsorMyovant Sciences GmbHRan2017 to 2020Enrolled382ConditionsHeavy Menstrual Bleeding, Uterine FibroidArmsRelugolix, Estradiol/norethindrone acetate, Relugolix placebo, Estradiol/norethindrone acetate placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Prevalence and associated risk factors of uterine fibroids in the Kingdom of Eswatini.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Elke HunscheDepartment of Global Market Access & HEOR, Myovant Sciences GmbH, Basel, Switzerland.ORCID https://orcid.org/0000-0002-5611-0554
Viatcheslav RakovGlobal Market Access and Health Economics/Outcomes Research, Myovant Sciences GmbH, Basel, Switzerland.
Kayla ScippaEndpoint Outcomes, Long Beach, California, USA.
Brooke WitherspoonEndpoint Outcomes, Boston, Massachusetts, USA.
Laura McKainMyovant Sciences, Inc., Brisbane, California, USA.
Health Outcomes Solutions (United States) · USMyovant Sciences (United States) · USHealth Economics and Outcomes Research (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Research on women's perspective of uterine fibroids (UF) experiences using their own words is limited. This study aimed to provide new insights on the symptoms experienced and their impacts on daily life. Methods: Interview substudy in 30 US women with heavy menstrual bleeding (HMB) associated with UF who completed one of two phase 3, randomized, double-blind, placebo-controlled trials (LIBERTY 1 and 2; ClinicalTrials.gov identifiers: NCT03049735, NCT03103087). Women who consented to participate in this substudy were interviewed after their last clinical trial study visit. Concepts ( Results: Fifteen unique symptoms of UF emerged: the most commonly reported were HMB ( Conclusion: This study provides data on the symptoms experienced by women with HMB associated with UF, as well as the negative impacts of these symptoms as reported using their own words. The study findings confirm the significant burden associated with symptomatic UF.

Indexed as

burdenconcept elicitationinterviewpatient perspectiveuterine fibroids

Identifiers

PMID35415708
PMCPMC8994433
OpenAlexW4220889066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.